Ortega NeuroRx continues to make meaningful progress as it advances its therapeutic development strategy and prepares for its next phase of growth.

The company was formed through the strategic separation of TNeuroPharma’s diagnostic and therapeutic assets—a decision driven by distinct investor priorities. By creating two focused entities—TNeuroDX for diagnostics and Ortega NeuroRx for therapeutics—the organization is better positioned to align each opportunity with the right investor base and accelerate development.

Over the past four months, the Ortega NeuroRx Board has worked closely with the New Mexico Start-Up Factory to define a clear and intentional roadmap for the company’s future. With additional guidance from an external consultant, the team has developed a strategic plan designed to support long-term growth and scientific advancement.

A central focus of this plan is the recruitment of a domain-expert Chief Executive Officer to lead the company forward. This leader will play a critical role in shaping the company’s fundraising strategy and guiding the scientific team in identifying the therapeutic indication with the greatest potential impact in the treatment of Alzheimer’s disease.

To support this effort, the Board has engaged a specialized executive search firm and has already identified a strong pool of candidates. Eight individuals have been interviewed to date, and the Board is currently conducting due diligence and reference checks to ensure alignment with the company’s vision, culture, and long-term goals.

As Ortega NeuroRx continues to build its leadership team and refine its strategic direction, additional updates are expected in the coming months.